Literature DB >> 3677296

Distribution of nitroimidazoles and L-phenylalanine mustard in mammary adenocarcinoma 16/C tumors.

P E Noker1, L Simpson-Herren, S D Wagoner.   

Abstract

Using the triphenylmethane dye, lissamine green, as an indicator of blood perfusion, we have demonstrated that L-phenylalanine mustard (L-PAM) is differentially distributed in mice bearing mammary adenocarcinoma 16/C tumors. Following i.p. administration, concentrations of L-PAM in various regions of the tumors vary by as much as 10-fold or more between regions of low and high perfusion. Since the nitroimidazoles, metronidazole and misonidazole, increase the cytotoxicity of certain antitumor agents, these compounds were investigated for their ability to increase the distribution of L-PAM into tumor regions of low perfusion. Administration of metronidazole (400 mg/kg) or misonidazole (800 mg/kg) 1 h prior to L-PAM and lissamine green resulted in elevated plasma levels of L-PAM and increased concentrations of L-PAM in tumor regions of high perfusion. A slight increase in the normally low levels of L-PAM in tumor regions of low perfusion was observed but the increase was not statistically significant. In contrast to the uneven distribution of L-PAM, metronidazole and misonidazole were evenly distributed throughout plasma and tumor regions of both high and low perfusion. Bioassay of tumors following in vivo exposure to metronidazole and L-PAM indicated decreased viability in fragments from tumor regions of high perfusion, but not from tumor regions of low perfusion. These studies demonstrate that the nitroimidazoles increased L-PAM levels in plasma and in tumor regions of both high and low perfusion but did not induce a uniform distribution of L-PAM throughout the tumors. The nitroimidazoles may enhance the effectiveness of L-PAM as an antitumor agent by increasing the concentration of drug that reaches a tumor.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3677296     DOI: 10.1007/bf00570482

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  25 in total

1.  EXPERIMENTS ON DETERMINATION OF MELPHALAN BY FLUORESCENCE. INTERACTION WITH PROTEIN AND VARIOUS SOLUTIONS.

Authors:  M A CHIRIGOS; J A MEAD
Journal:  Anal Biochem       Date:  1964-03       Impact factor: 3.365

Review 2.  L-phenylalanine mustard (L-PAM): the first 25 years.

Authors:  R L Furner; R K Brown
Journal:  Cancer Treat Rep       Date:  1980 Apr-May

3.  Antitumor drug toxicity in tumor-free and tumor-bearing mice.

Authors:  S D Harrison; H D Giles; E P Denine
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

4.  Regional measurements of [14C]misonidazole distribution and blood flow in subcutaneous RT-9 experimental tumors.

Authors:  R Blasberg; M Horowitz; J Strong; P Molnar; C Patlak; E Owens; J Fenstermacher
Journal:  Cancer Res       Date:  1985-04       Impact factor: 12.701

5.  In vitro degradation of L-phenylalanine mustard (L-PAM).

Authors:  T L Evans; S Y Chang; D S Alberts; I G Sipes; K Brendel
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  Variability of tumor response to chemotherapy. II. Contribution of tumor heterogeneity.

Authors:  L Simpson-Herren; P E Noker; S D Wagoner
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Factors influencing the chemosensitization of melphalan by misonidazole.

Authors:  V S Randhawa; F A Stewart; J Denekamp; M R Stratford
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

8.  Distribution of misonidazole in human tumours and normal tissues.

Authors:  D V Ash; M R Smith; R D Bugden
Journal:  Br J Cancer       Date:  1979-05       Impact factor: 7.640

9.  Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain.

Authors:  D G Hirst; J M Brown; J L Hazlehurst
Journal:  Br J Cancer       Date:  1982-07       Impact factor: 7.640

10.  Metronidazole (Flagyl): characterization as a cytotoxic drug specific for hypoxic tumour cells.

Authors:  J L Foster; P J Conroy; A J Searle; R L Willson
Journal:  Br J Cancer       Date:  1976-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.